FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386784474> ?p ?o ?g. }

• W4386784474 endingPage "005" @default.
• W4386784474 startingPage "PO" @default.
• W4386784474 abstract "Abstract The project pursues clinical testing of a gene-based treatment for refractory malignancy of the head and neck. Background We are evaluating intratumoral nucleoside cleavage by E. coli purine nucleoside phosphorylase (PNP) as an experimental therapy for refractory solid tumors. The approach requires delivery of PNP transgene to tumor parenchyma followed by prodrug administration, and provides “bystander” killing by a very potent purine antimetabolite (F-Ade) generated intratumorally. F-Ade is 1,000-times more potent than fluorouracil, the chemotherapeutic produced by cytosine deaminase (CD; a first-generation construct used for tumor sensitization). PNP/F-Ade has been found to be superior to CD/fluorouracil by several laboratories. In a Phase 1 study (Rosenthal et al., Ann. Oncol.), antitumor activity was observed after IT injections of a recombinant adenovirus encoding PNP (Ad/PNP), followed by IV fludarabine phosphate (F-araAMP, a prodrug converted by PNP to F-Ade). Methods Patients in the present trial have RECIST 1.1 measurable HNSCC amenable to local injection and no other palliative treatment options. A single-arm protocol is being used to evaluate safety of repeat cycles of Ad/PNP and F-araAMP. Ad/PNP is injected intratumorally twice on Day 1 and once on Day 2, followed by infusion of F-araAMP on Days 3, 4, and 5 every 4 weeks for up to 5 cycles. Results Eight patients have been enrolled to date. There have been no dose limiting toxicities, no serious adverse events (SAEs) definitively attributable to treatment, and no AEs above grade 3 severity. Up to five cycles of Ad/PNP treatment have been administered without limiting sequelae. Intratumoral expression of PNP transgene by RT-PCR has been established in treated tumors. Other correlative endpoints are in process and will be discussed. One patient exhibited tumor volume reduction by approximately 21% (as judged by CT imaging) and did not increase during five months of treatment, consistent with clinically stable disease. Two other patients completed three months of Ad/PNP with stable disease by RECIST criteria during the treatment period. Another patient’s tumor (largest dimension 3.1 cm) demonstrated 25% decrease after one treatment cycle. Challenges have included: 1) complexity of distribution of agent into large volume tumors (e.g., &gt;100 ml) with small volume of Ad/PNP, and 2) acute swelling of tumor tissue following intratumoral virus injection in two patients, consistent with inflammatory response and/or disease progression. Conclusions Administration of Ad/PNP is safe and feasible. Injections of large volume tumors remains a challenge. The strategy is also being considered for earlier-stage HNSCC with less tumor burden, including a role similar to neoadjuvant or cytoreductive radiotherapy in combination with checkpoint blockade inhibition. A muti-center trial is planned to define MTD and feasibility in smaller tumors. Citation Format: A. Dimitrios Colevas, Eric J. Sorscher, William B. Parker, Roan Courtney Raymundo, Jeong S. Hong, Regina Rab, Camilo Henao, Nikki Schmitt, Madison Stallings, Kelly T. McKee, Eben Rosenthal, Joseph Curry. Phase 1/2 study of Ad/PNP with fludarabine for the treatment of head & neck squamous cell carcinoma (HNSCC) [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-005." @default.
• W4386784474 created "2023-09-16" @default.
• W4386784474 creator A5006170510 @default.
• W4386784474 creator A5009727776 @default.
• W4386784474 creator A5015026678 @default.
• W4386784474 creator A5040920263 @default.
• W4386784474 creator A5050704941 @default.
• W4386784474 creator A5051505018 @default.
• W4386784474 creator A5057995830 @default.
• W4386784474 creator A5058155286 @default.
• W4386784474 creator A5064978721 @default.
• W4386784474 creator A5069613777 @default.
• W4386784474 creator A5086275218 @default.
• W4386784474 creator A5091626287 @default.
• W4386784474 date "2023-09-15" @default.
• W4386784474 modified "2023-10-07" @default.
• W4386784474 title "Abstract PO-005: Phase 1/2 study of Ad/PNP with fludarabine for the treatment of head & neck squamous cell carcinoma (HNSCC)" @default.
• W4386784474 doi "https://doi.org/10.1158/1557-3265.aacrahns23-po-005" @default.
• W4386784474 hasPublicationYear "2023" @default.
• W4386784474 type Work @default.
• W4386784474 citedByCount "0" @default.
• W4386784474 crossrefType "journal-article" @default.
• W4386784474 hasAuthorship W4386784474A5006170510 @default.
• W4386784474 hasAuthorship W4386784474A5009727776 @default.
• W4386784474 hasAuthorship W4386784474A5015026678 @default.
• W4386784474 hasAuthorship W4386784474A5040920263 @default.
• W4386784474 hasAuthorship W4386784474A5050704941 @default.
• W4386784474 hasAuthorship W4386784474A5051505018 @default.
• W4386784474 hasAuthorship W4386784474A5057995830 @default.
• W4386784474 hasAuthorship W4386784474A5058155286 @default.
• W4386784474 hasAuthorship W4386784474A5064978721 @default.
• W4386784474 hasAuthorship W4386784474A5069613777 @default.
• W4386784474 hasAuthorship W4386784474A5086275218 @default.
• W4386784474 hasAuthorship W4386784474A5091626287 @default.
• W4386784474 hasConcept C104317684 @default.
• W4386784474 hasConcept C108215921 @default.
• W4386784474 hasConcept C111599444 @default.
• W4386784474 hasConcept C121608353 @default.
• W4386784474 hasConcept C126322002 @default.
• W4386784474 hasConcept C143998085 @default.
• W4386784474 hasConcept C197934379 @default.
• W4386784474 hasConcept C2776530083 @default.
• W4386784474 hasConcept C2776543447 @default.
• W4386784474 hasConcept C2776694085 @default.
• W4386784474 hasConcept C2776755627 @default.
• W4386784474 hasConcept C2776833033 @default.
• W4386784474 hasConcept C2777333352 @default.
• W4386784474 hasConcept C2777748644 @default.
• W4386784474 hasConcept C2778397455 @default.
• W4386784474 hasConcept C2779263901 @default.
• W4386784474 hasConcept C2780258809 @default.
• W4386784474 hasConcept C29730261 @default.
• W4386784474 hasConcept C502942594 @default.
• W4386784474 hasConcept C55493867 @default.
• W4386784474 hasConcept C71924100 @default.
• W4386784474 hasConcept C86803240 @default.
• W4386784474 hasConcept C98274493 @default.
• W4386784474 hasConceptScore W4386784474C104317684 @default.
• W4386784474 hasConceptScore W4386784474C108215921 @default.
• W4386784474 hasConceptScore W4386784474C111599444 @default.
• W4386784474 hasConceptScore W4386784474C121608353 @default.
• W4386784474 hasConceptScore W4386784474C126322002 @default.
• W4386784474 hasConceptScore W4386784474C143998085 @default.
• W4386784474 hasConceptScore W4386784474C197934379 @default.
• W4386784474 hasConceptScore W4386784474C2776530083 @default.
• W4386784474 hasConceptScore W4386784474C2776543447 @default.
• W4386784474 hasConceptScore W4386784474C2776694085 @default.
• W4386784474 hasConceptScore W4386784474C2776755627 @default.
• W4386784474 hasConceptScore W4386784474C2776833033 @default.
• W4386784474 hasConceptScore W4386784474C2777333352 @default.
• W4386784474 hasConceptScore W4386784474C2777748644 @default.
• W4386784474 hasConceptScore W4386784474C2778397455 @default.
• W4386784474 hasConceptScore W4386784474C2779263901 @default.
• W4386784474 hasConceptScore W4386784474C2780258809 @default.
• W4386784474 hasConceptScore W4386784474C29730261 @default.
• W4386784474 hasConceptScore W4386784474C502942594 @default.
• W4386784474 hasConceptScore W4386784474C55493867 @default.
• W4386784474 hasConceptScore W4386784474C71924100 @default.
• W4386784474 hasConceptScore W4386784474C86803240 @default.
• W4386784474 hasConceptScore W4386784474C98274493 @default.
• W4386784474 hasIssue "18_Supplement" @default.
• W4386784474 hasLocation W43867844741 @default.
• W4386784474 hasOpenAccess W4386784474 @default.
• W4386784474 hasPrimaryLocation W43867844741 @default.
• W4386784474 hasRelatedWork W1978805491 @default.
• W4386784474 hasRelatedWork W1992859406 @default.
• W4386784474 hasRelatedWork W2093944145 @default.
• W4386784474 hasRelatedWork W2113566724 @default.
• W4386784474 hasRelatedWork W2119596897 @default.
• W4386784474 hasRelatedWork W2151634703 @default.
• W4386784474 hasRelatedWork W2297302537 @default.
• W4386784474 hasRelatedWork W2412717638 @default.
• W4386784474 hasRelatedWork W2792421861 @default.
• W4386784474 hasRelatedWork W3037479272 @default.
• W4386784474 hasVolume "29" @default.
• W4386784474 isParatext "false" @default.
• W4386784474 isRetracted "false" @default.
• W4386784474 workType "article" @default.